Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, 13 to 17 years of age who must not yet have reached their 18th birthday prior to Visit 1, when informed consent is obtained.~* Patients must have a diagnosis of bipolar I disorder and currently display an acute mania or mixed episode.~* Both the patient and the patient's parent/authorized legal representative must understand the nature of the study and must sign a document granting consent.~* Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test.~Exclusion Criteria:~* Female patients who are either pregnant or nursing.~* Current diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder.~* Patient with acute or unstable medical conditions, such that intensive care unit hospitalization for the disease is anticipated within 6 months.~* Patients who have previously not responded to an adequate dose and/or duration of olanzapine treatment.~* Patients who have been judged clinically to be serious suicidal risks.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).